Skip to main content

Protocol of CLOuD of published in the BMJ

A research protocol for a randomised parallel study assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy has been published in the British Medical Journal, on behalf of the CLOuD Consortium.


Prof R Hovorka
Professor Roman Hovorka

Professor of Metabolic Technology, University of Cambridge

The CLOuD study builds on recent technological advances of closed-loop insulin delivery (artificial pancreas). The purpose of this study is to test the impact of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion.

The primary objective is to evaluate the effect of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion by comparing the area under the stimulated C-peptide curve (AUC) of a mixed meal glucose tolerance test conducted at the 12-month visit in participants receiving closed-loop insulin delivery with those receiving standard therapy, i.e. multiple daily injections applying basal-bolus regimen.

Published April 22, 2020

Latest from CCTU

National Patient Led Research Hub celebrates tenth anniversary

A national team based in Cambridge are celebrating ten years of helping people living with rare diseases to develop their own research ideas. The hub has…

Hope for MS patients as Cambridge trial suggests drug combination may repair nerve damage

Early findings from a clinical trial in Cambridge suggest a combination of metformin, a diabetes drug, and clemastine, an antihistamine, can help repair…

Prospective study into controversial brain cyst syndrome is world first

The world’s first study of its kind highlights the potential value of surgery to treat a specific kind of brain cyst that blights the lives of patients.

All news